pubmed-article:10637495 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:10637495 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
pubmed-article:10637495 | lifeskim:mentions | umls-concept:C0026764 | lld:lifeskim |
pubmed-article:10637495 | lifeskim:mentions | umls-concept:C0007620 | lld:lifeskim |
pubmed-article:10637495 | lifeskim:mentions | umls-concept:C0003250 | lld:lifeskim |
pubmed-article:10637495 | lifeskim:mentions | umls-concept:C0243192 | lld:lifeskim |
pubmed-article:10637495 | lifeskim:mentions | umls-concept:C0018284 | lld:lifeskim |
pubmed-article:10637495 | lifeskim:mentions | umls-concept:C0040661 | lld:lifeskim |
pubmed-article:10637495 | lifeskim:mentions | umls-concept:C1705162 | lld:lifeskim |
pubmed-article:10637495 | pubmed:issue | 1 | lld:pubmed |
pubmed-article:10637495 | pubmed:dateCreated | 2000-2-2 | lld:pubmed |
pubmed-article:10637495 | pubmed:abstractText | We have previously reported obtaining two monoclonal antibodies (mAb) against the human gp130 interleukin-6 (IL-6) transducer which made possible the dimerization of gp130 and the activation of several IL-6-driven functions when used together. We report here that these mAb induce gp130-mediated signaling in human myeloma cells and support the survival and the long-term growth of five IL-6-dependent human myeloma cell lines. Their agonist activity is not affected by neutralizing antibodies to IL-6 or IL-6R. These mAb induce a transient proliferation of primary myeloma cells from most patients with multiple myeloma. Again, IL-6 inhibitors do not affect this agonist activity. By using highly purified primary myeloma cells, we found that these anti-gp130 mAb supported the long-term survival of primary myeloma cells from five patients with primary plasma cell leukemia but failed to induce their long-term growth. For patients with fulminant disease and secondary extramedullary proliferation, the antibodies supported a long-term survival and growth, and anti-gp130 mAb-dependent cell lines were obtained. For patients with medullary involvement only, a co-stimulatory signal is necessary, together with gp130 activation, to trigger cell survival and cycling. Leukemia (2000) 14, 188-197. | lld:pubmed |
pubmed-article:10637495 | pubmed:language | eng | lld:pubmed |
pubmed-article:10637495 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:10637495 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:10637495 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:10637495 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:10637495 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:10637495 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:10637495 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:10637495 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:10637495 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:10637495 | pubmed:month | Jan | lld:pubmed |
pubmed-article:10637495 | pubmed:issn | 0887-6924 | lld:pubmed |
pubmed-article:10637495 | pubmed:author | pubmed-author:WijdenesJJ | lld:pubmed |
pubmed-article:10637495 | pubmed:author | pubmed-author:KleinBB | lld:pubmed |
pubmed-article:10637495 | pubmed:author | pubmed-author:ZhangX GXG | lld:pubmed |
pubmed-article:10637495 | pubmed:author | pubmed-author:De VosJJ | lld:pubmed |
pubmed-article:10637495 | pubmed:author | pubmed-author:RossiJ FJF | lld:pubmed |
pubmed-article:10637495 | pubmed:author | pubmed-author:JourdanMM | lld:pubmed |
pubmed-article:10637495 | pubmed:author | pubmed-author:GuZ JZJ | lld:pubmed |
pubmed-article:10637495 | pubmed:author | pubmed-author:RebouissouCC | lld:pubmed |
pubmed-article:10637495 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:10637495 | pubmed:volume | 14 | lld:pubmed |
pubmed-article:10637495 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:10637495 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:10637495 | pubmed:pagination | 188-97 | lld:pubmed |
pubmed-article:10637495 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
pubmed-article:10637495 | pubmed:meshHeading | pubmed-meshheading:10637495... | lld:pubmed |
pubmed-article:10637495 | pubmed:meshHeading | pubmed-meshheading:10637495... | lld:pubmed |
pubmed-article:10637495 | pubmed:meshHeading | pubmed-meshheading:10637495... | lld:pubmed |
pubmed-article:10637495 | pubmed:meshHeading | pubmed-meshheading:10637495... | lld:pubmed |
pubmed-article:10637495 | pubmed:meshHeading | pubmed-meshheading:10637495... | lld:pubmed |
pubmed-article:10637495 | pubmed:meshHeading | pubmed-meshheading:10637495... | lld:pubmed |
pubmed-article:10637495 | pubmed:meshHeading | pubmed-meshheading:10637495... | lld:pubmed |
pubmed-article:10637495 | pubmed:meshHeading | pubmed-meshheading:10637495... | lld:pubmed |
pubmed-article:10637495 | pubmed:meshHeading | pubmed-meshheading:10637495... | lld:pubmed |
pubmed-article:10637495 | pubmed:meshHeading | pubmed-meshheading:10637495... | lld:pubmed |
pubmed-article:10637495 | pubmed:meshHeading | pubmed-meshheading:10637495... | lld:pubmed |
pubmed-article:10637495 | pubmed:meshHeading | pubmed-meshheading:10637495... | lld:pubmed |
pubmed-article:10637495 | pubmed:meshHeading | pubmed-meshheading:10637495... | lld:pubmed |
pubmed-article:10637495 | pubmed:year | 2000 | lld:pubmed |
pubmed-article:10637495 | pubmed:articleTitle | Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors. | lld:pubmed |
pubmed-article:10637495 | pubmed:affiliation | INSERM U475, Immunopathologie des Maladies Tumorales et Autoimmmunes, Montpellier, France. | lld:pubmed |
pubmed-article:10637495 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:10637495 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10637495 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10637495 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10637495 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10637495 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10637495 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10637495 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10637495 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10637495 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10637495 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10637495 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10637495 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10637495 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10637495 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10637495 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10637495 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10637495 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10637495 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10637495 | lld:pubmed |